Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Xeris Biopharma reported $54.27 million in revenue for Q3 2024, marking a 12.3% year-over-year increase and a 5.09% surprise over the Zacks Consensus Estimate of $51.64 million [1] - The company posted an EPS of -$0.06, which is an improvement from -$0.09 a year ago, resulting in a 33.33% EPS surprise compared to the consensus estimate [1] Revenue Breakdown - Gvoke product revenue was $22.94 million, slightly below the estimated $22.97 million [3] - Keveyis product revenue reached $12.19 million, compared to the estimated $12.50 million [3] - Recorlev product revenue was $17.73 million, exceeding the estimated $15.07 million [3] - Total net product revenue was $52.86 million, surpassing the estimated $50.53 million [3] - Revenue from royalties, contracts, and other sources was $1.41 million, exceeding the estimated $0.93 million [3] Stock Performance - Xeris Biopharma shares have increased by 20.9% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.9% [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]